ArticlePLoS pathogens2013

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Patrizia Nanni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.